APA (7th ed.) Citation

B, W., CM, S., K, E., AJ, G., SMA, M., SW, E., . . . RB, L. (2025). The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia. HemaSphere, 9(1), e70063. https://doi.org/10.1002/hem3.70063

Chicago Style (17th ed.) Citation

B, Watts, et al. "The CD123 Antibody-drug Conjugate Pivekimab Sunirine Exerts Profound Activity in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia." HemaSphere 9, no. 1 (2025): e70063. https://doi.org/10.1002/hem3.70063.

MLA (9th ed.) Citation

B, Watts, et al. "The CD123 Antibody-drug Conjugate Pivekimab Sunirine Exerts Profound Activity in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia." HemaSphere, vol. 9, no. 1, 2025, p. e70063, https://doi.org/10.1002/hem3.70063.